GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » Notes Receivable

ORKA (Oruka Therapeutics) Notes Receivable : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Notes Receivable?

Oruka Therapeutics's Notes Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.


Oruka Therapeutics Notes Receivable Historical Data

The historical data trend for Oruka Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Notes Receivable Chart

Oruka Therapeutics Annual Data
Trend Dec24
Notes Receivable
-

Oruka Therapeutics Quarterly Data
Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable - - - - -

Oruka Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Oruka Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.